View More Recent Stories
-
Ionis Pharmaceuticals (IONS) Announces Proposed $500M Share Offering
-
Biogen (BIIB) Reports Positive Topline Results from Study of Higher Dose Regimen of Nusinersen
-
BMO Capital Downgrades Ionis Pharmaceuticals (IONS) to Market Perform
-
Ionis Pharmaceuticals (IONS) Tops Q2 EPS by 48c
-
RBC's biotech survey shows investors more bearish vs. last time
-
Leerink Partners Upgrades Ionis Pharmaceuticals (IONS) to Outperform
-
Ionis Pharmaceuticals (IONS) PT Raised to $59 at TD Cowen
-
BMO Capital Reiterates Outperform Rating on Ionis Pharmaceuticals (IONS)
-
Ionis Pharmaceuticals (IONS) PT Raised to $77 at Jefferies
-
Goldman Sachs Reiterates Sell Rating on Ionis Pharmaceuticals (IONS)
-
Ionis Pharmaceuticals (IONS) announces positive detailed results from the HALOS Study of ION582 in people with Angelman syndrome
-
Jefferies Double Upgrades Ionis Pharmaceuticals (IONS) to Buy
-
Ionis Pharmaceuticals (IONS) PT Raised to $53 at Stifel
-
Ionis Pharmaceuticals (IONS) announces olezarsen FCS New Drug Application accepted for Priority Review and enrollment in Phase 3 sHTG program completed
-
TD Cowen Reiterates Buy Rating on Ionis Pharmaceuticals (IONS)
-
Alnylam (ALNY) data is positive for Ionis (IONS), Intellia (NTLA) and negative for BridgeBio (BBIO) - analyst
-
Ionis Pharmaceuticals (IONS) expanded licensing agreement with Otsuka in Asia Pacific for investigational medicine donidalorsen in hereditary angioedema
-
RBC Capital Reiterates Outperform Rating on Ionis Pharmaceuticals (IONS)
-
Bernstein SocGen Group Upgrades Ionis Pharmaceuticals (IONS) to Market Perform

